Evidence map›Paper›PMID 29766345›Full record

ArticleDocumenta ophthalmologica. Advances in ophthalmology2018

Visual function assessed by visually evoked potentials in optic pathway low-grade gliomas with and without neurofibromatosis type 1.

Patrícia de Freitas Dotto, Adriana Berezovsky, Andrea Maria Cappellano, Nasjla Saba da Silva, Paula Yuri Sacai, Frederico Adolfo B Silva, Arthur Gustavo Fernandes, Daniel Martins Rocha, Solange Rios Salomão

Abstract read
PubMed Publisher
In one paragraph

Article in Documenta ophthalmologica. Advances in ophthalmology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Patrícia de Freitas DottoLaboratório de Eletrofisiologia Visual Clínica, Departamento de Oftalmologia e Ciências Visuais, Escola Paulista de Medicina, Universidade Federal de São Paulo - UNIFESP, R. Botucatu 821, São Paulo, SP, 04023-062, Brazil.
Adriana BerezovskyLaboratório de Eletrofisiologia Visual Clínica, Departamento de Oftalmologia e Ciências Visuais, Escola Paulista de Medicina, Universidade Federal de São Paulo - UNIFESP, R. Botucatu 821, São Paulo, SP, 04023-062, Brazil.
Andrea Maria CappellanoPrograma de Neuro-Oncologia, Instituto de Oncologia Pediátrica, Grupo de Apoio ao Adolescente e à Criança com Câncer (IOP-GRAAC), Universidade Federal de São Paulo - UNIFESP, São Paulo, SP, Brazil.
Nasjla Saba da SilvaPrograma de Neuro-Oncologia, Instituto de Oncologia Pediátrica, Grupo de Apoio ao Adolescente e à Criança com Câncer (IOP-GRAAC), Universidade Federal de São Paulo - UNIFESP, São Paulo, SP, Brazil.
Paula Yuri SacaiLaboratório de Eletrofisiologia Visual Clínica, Departamento de Oftalmologia e Ciências Visuais, Escola Paulista de Medicina, Universidade Federal de São Paulo - UNIFESP, R. Botucatu 821, São Paulo, SP, 04023-062, Brazil.
Frederico Adolfo B SilvaPrograma de Neuro-Oncologia, Instituto de Oncologia Pediátrica, Grupo de Apoio ao Adolescente e à Criança com Câncer (IOP-GRAAC), Universidade Federal de São Paulo - UNIFESP, São Paulo, SP, Brazil.
Arthur Gustavo FernandesLaboratório de Eletrofisiologia Visual Clínica, Departamento de Oftalmologia e Ciências Visuais, Escola Paulista de Medicina, Universidade Federal de São Paulo - UNIFESP, R. Botucatu 821, São Paulo, SP, 04023-062, Brazil.
Daniel Martins RochaLaboratório de Eletrofisiologia Visual Clínica, Departamento de Oftalmologia e Ciências Visuais, Escola Paulista de Medicina, Universidade Federal de São Paulo - UNIFESP, R. Botucatu 821, São Paulo, SP, 04023-062, Brazil.
Solange Rios SalomãoLaboratório de Eletrofisiologia Visual Clínica, Departamento de Oftalmologia e Ciências Visuais, Escola Paulista de Medicina, Universidade Federal de São Paulo - UNIFESP, R. Botucatu 821, São Paulo, SP, 04023-062, Brazil. ssalomao@unifesp.br.
Universidade Federal de São Paulo · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo investigate the contribution of full-field transient pattern-reversal visually evoked potentials (PRVEP) on cross-sectional evaluations of visual function in patients with and without neurofibromatosis type 1 (NF1) affected by optic pathway low-grade gliomas (OPLGG).

methodsParticipants were children and adolescents referred for visual function evaluation and receiving treatment for OPLGG, linked (NF1-OPLGG) or not to NF1 (Non-NF1-OPLGG). An age-adjusted control group was included for comparison. Monocular full-field PRVEPs were recorded from each eye in accordance with ISCEV standards. Parameters of peak-to-peak P100 amplitude (µV) and P100 peak time (ms) were measured. Cutoff normative values obtained from controls for 15' and 60' check sizes were ≥ 9.0 µV for N75-P100 amplitude and ≤ 103.0 ms for P100 peak time. The association of age, gender, tumor resection and NF1 with P100 amplitude reduction and P100 peak time delay was explored by Firth logistic regression modeling.

resultsParticipants were 30 patients (15 males, 60% Non-NF1) with ages from 3.6 to 19.9 years (mean ± SD = 9.2 ± 3.8 years; median = 8.4 years) and 19 controls (12 males) with ages from 3.7 to 19.9 years (mean ± SD = 10.4 ± 4.9 years; median = 9.5 years). Overall, 68% of tested eyes presented reduced P100 amplitudes for both check sizes (46% in the NF-1 and 83% in the Non-NF1) and delayed P100 for both check sizes (38% in NF1 and 89% in Non-NF1). Absence of NF1 adjusted for age, gender and tumor resection was significantly associated with marginally reduced P100 amplitude for 15' checks [odds ratio (OR): 6.26; 95% confidence interval (CI) = 0.96-40.94; p = 0.055].

conclusionsFull-field PRVEP on cross-sectional evaluations contributed to detect visual dysfunction in two-thirds of patients with OPLGG by highlighting subclinical evidence of visual loss. Abnormalities were more frequent and more severe in OPLGG not linked to NF1 than in NF1-OPLGG; however, there was a difference in surgical management between these groups. PRVEP parameters may provide reliable evidence of visual pathway involvement in OPLGG, helping to hasten treatment before optic atrophy is detected.

Indexed as

AdolescentChildChild, PreschoolCross-Sectional StudiesEvoked Potentials, VisualFemaleHumansMaleNeurofibromatosis 1Optic Nerve GliomaVision DisordersVision TestsVisual AcuityVisual PathwaysYoung AdultChildhoodOptic pathway gliomaPattern reversalVisually evoked potentialsVisual pathways

Identifiers

PMID29766345
OpenAlexW2804931129

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.